Table 2.
Published in | Spe-cies | Sex | Dose(s) | Route | Time before test | Region(s) | Behavioral test(s) | Main findings |
---|---|---|---|---|---|---|---|---|
Khisti and Chopde (2000) | mice | ♂ | 1 × 0.5–2 mg/kg 1 × 0.5–2 μg/mouse |
i.p. m.i. |
30 min 15 min |
|
|
|
Khisti et al. (2000) | mice | ♂ | 1 × 0.5–2 mg/kg 1 × 0.5–2 μg/mouse |
i.p. m.i. |
30 min 15 min |
|
|
|
Molina-Hernández et al. (2005) | rats | ♀ | 21 × 0.5–2 mg/kg/d 1 × 1–4 μg/rat |
s.c. m.i. |
30 min 15 min |
|
|
|
Rodríguez-Landa et al. (2007) | mice | ♀OVX | 1 × 0.5–3 mg/kg | i.p. | 1 h |
|
|
|
Pibiri et al. (2006) | mice | ♂+♀ | 1 × 1.25–5 mg/kg | i.p. | 30 min |
|
|
|
Naert et al. (2007) | rats | ♂ | 1 × 0.05 mg/kg | i.p. | 15–300 min |
|
|
|
Nin et al. (2008) | rats | ♂ | 3 × 1.25–5 μg/rat | m.i. | 24, 5, 1 h |
|
|
|
Rodríguez-Landa et al. (2009) | rats | ♂ | 1 × 2 μg/rat | m.i. | immedia-tely |
|
|
|
Shirayama et al. (2011) | rats | ♂ | 1 × 0.1 or 1 μg/rat | m.i. | 4 d |
|
|
|
Evans et al. (2012) | rats | ♂ | 50 mg released over 50 days | s.c. |
|
|
|
|
Nin et al. (2012) | rats | ♂ | 3 × 1.25–5 μg/rat | m.i. | 24, 5, 1 h |
|
|
|
Almeida et al. (2018) | rats | ♂ | 3 × 5 μg/rat | m.i. | 24, 5, 1 h |
|
|
|
Almeida et al. (2019) | rats | ♂ | 3 × 1.25–5 μg/rat | m.i. | 24, 5, 1 h |
|
|
|
Abbreviations and legends: increases (↑); decreases (↓); does not change (≌); ovariectomy (OVX); systemic (syst.); intraperitoneally (i.p.); subcutaneously (s.c.); microinjection (m.i.); hippocampus (HPC); dentate gyrus (DG); dorsal (D); lateral septum (LS); septofimbrial (SF); prefrontal cortex (PFC); central amygdala (CeA); basolateral amygdala (BLA); cerebral ventricle (CV); nucleus accumbens (NAcc); forced swim test (FST); open field test (OFT); resident-intruder test (RIT); learned helplessness test (LHT); novelty-suppressed feeding test (NSFT); microstructured grooming (M-Groom); latency (lat.).